Tyra Biosciences (NASDAQ:TYRA) Given “Outperform” Rating at Wedbush

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $30.00 price target on the stock. Wedbush’s target price indicates a potential upside of 203.80% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Stock Up 2.2 %

Shares of TYRA stock traded up $0.22 during trading hours on Friday, hitting $9.88. 88,835 shares of the company’s stock traded hands, compared to its average volume of 231,537. Tyra Biosciences has a 12 month low of $9.49 and a 12 month high of $29.60. The stock has a market cap of $499.70 million, a PE ratio of -6.14 and a beta of 1.09. The stock’s 50 day simple moving average is $12.59 and its 200 day simple moving average is $16.45.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. As a group, equities research analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Activity at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Tyra Biosciences by 2.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after acquiring an additional 3,792 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Tyra Biosciences in the 3rd quarter worth approximately $333,000. FMR LLC increased its position in shares of Tyra Biosciences by 0.8% during the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after acquiring an additional 26,187 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Tyra Biosciences in the third quarter worth $593,000. Finally, Walleye Capital LLC grew its position in Tyra Biosciences by 306.5% during the third quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock valued at $2,976,000 after buying an additional 95,451 shares during the period. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.